Medicine and Dentistry
Acute Drug Administration
6%
Amisulpride
10%
Antipsychotic
50%
Aripiprazole
10%
Biomedical Research
10%
Body Mass Index
30%
Body Weight
10%
Brexpiprazole
30%
Brief Psychiatric Rating Scale
10%
Cannabidiol
8%
Cannabis
25%
Cannabis Use
5%
Cariprazine
30%
Clinician
10%
Clozapine
50%
Effect Size
17%
Haloperidol
20%
High Density Lipoprotein Cholesterol
30%
Ketamine
25%
Low Density Lipoprotein Cholesterol
25%
Lurasidone
20%
Medical Research
7%
Meta-Analysis
50%
Meta-Regression
10%
Negative Syndrome
7%
Network Meta-Analysis
50%
Olanzapine
30%
Placebo
38%
Positive and Negative Syndrome Scale
10%
Positive Syndrome
6%
Randomized Controlled Trial
20%
Side Effect
20%
Systematic Review
100%
Tetrahydrocannabinol
25%
Therapeutic Use
25%
Treatment Duration
10%
Treatment of Schizophrenia
10%
Triacylglycerol
20%
Water-Electrolyte Imbalance
20%
Ziprasidone
10%
Neuroscience
Amisulpride
10%
Antipsychotic
52%
Aripiprazole
10%
Bipolar Disorder
25%
Body Mass Index
30%
Brain Imaging
5%
Cannabidiol
8%
Cannabis
25%
Clozapine
50%
Fractional Anisotropy
25%
Gray Matter
11%
Haloperidol
20%
High Density Lipoprotein Cholesterol
30%
Ketamine
25%
Low Density Lipoprotein Cholesterol
25%
Lurasidone
20%
Major Depressive Disorder
16%
Mental Disorder
26%
Meta-Analysis
100%
Metabolic Disorder
20%
Microglia
5%
Monoclonal Antibody
5%
Natalizumab
19%
Negative Syndrome
23%
Nervous System Cell
25%
Olanzapine
30%
Placebo
47%
Positive Syndrome
22%
positron emission tomographic scan
8%
Randomized Controlled Trial
20%
Temporal Lobe
5%
Tetrahydrocannabinol
25%
Therapeutic Antibodies
25%
Translocator Protein
25%
Treatment of Schizophrenia
10%
Triacylglycerol
20%
Ziprasidone
10%
Pharmacology, Toxicology and Pharmaceutical Science
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
20%
Amisulpride
10%
Antipsychotic
50%
Aripiprazole
10%
Brexpiprazole
30%
Cannabidiol
8%
Cannabis
25%
Cariprazine
30%
Clozapine
50%
High Density Lipoprotein Cholesterol
30%
Ketamine
25%
Low Density Lipoprotein Cholesterol
25%
Lurasidone
20%
Metabolic Disorder
20%
Negative Syndrome
18%
Normal Human
6%
Olanzapine
30%
Placebo
38%
Positive Syndrome
17%
Randomized Controlled Trial
20%
Side Effect
20%
Tetrahydrocannabinol
25%
Therapeutic Use
25%
Triacylglycerol
20%
Ziprasidone
10%
